Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Hepatocellular 4Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Hepatoblastoma 1Fibrolamellar hepatocellular carcinoma 1

Interventions

Cyclophosphamide 7X-Rays 6Phantoms, Imaging 6Specimen Handling 5Magnetic Resonance Spectroscopy 5Nuclear Medicine Department, Hospital 4Carboplatin 4fludarabine 3Temozolomide 3Nivolumab 3Gemcitabine 3Filgrastim 3Biopsy 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2pembrolizumab 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2ensartinib 2belinostat 2Vemurafenib 2Topotecan 2Psychiatric Rehabilitation 2Oxaliplatin 2Mesna 2LY3023414 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Osteosarcoma × Tacrolimus × Gastrointestinal × Clear all
NCT01804634 2026-03-13

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
60 enrolled
CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡